Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
- PMID: 28700844
- DOI: 10.1056/NEJMoa1615869
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Abstract
Background: We previously found no significant differences in mortality between men who underwent surgery for localized prostate cancer and those who were treated with observation only. Uncertainty persists regarding nonfatal health outcomes and long-term mortality.
Methods: From November 1994 through January 2002, we randomly assigned 731 men with localized prostate cancer to radical prostatectomy or observation. We extended follow-up through August 2014 for our primary outcome, all-cause mortality, and the main secondary outcome, prostate-cancer mortality. We describe disease progression, treatments received, and patient-reported outcomes through January 2010 (original follow-up).
Results: During 19.5 years of follow-up (median, 12.7 years), death occurred in 223 of 364 men (61.3%) assigned to surgery and in 245 of 367 (66.8%) assigned to observation (absolute difference in risk, 5.5 percentage points; 95% confidence interval [CI], -1.5 to 12.4; hazard ratio, 0.84; 95% CI, 0.70 to 1.01; P=0.06). Death attributed to prostate cancer or treatment occurred in 27 men (7.4%) assigned to surgery and in 42 men (11.4%) assigned to observation (absolute difference in risk, 4.0 percentage points; 95% CI, -0.2 to 8.3; hazard ratio, 0.63; 95% CI, 0.39 to 1.02; P=0.06). Surgery may have been associated with lower all-cause mortality than observation among men with intermediate-risk disease (absolute difference, 14.5 percentage points; 95% CI, 2.8 to 25.6) but not among those with low-risk disease (absolute difference, 0.7 percentage points; 95% CI, -10.5 to 11.8) or high-risk disease (absolute difference, 2.3 percentage points; 95% CI, -11.5 to 16.1) (P=0.08 for interaction). Treatment for disease progression was less frequent with surgery than with observation (absolute difference, 26.2 percentage points; 95% CI, 19.0 to 32.9); treatment was primarily for asymptomatic, local, or biochemical (prostate-specific antigen) progression. Urinary incontinence and erectile and sexual dysfunction were each greater with surgery than with observation through 10 years. Disease-related or treatment-related limitations in activities of daily living were greater with surgery than with observation through 2 years.
Conclusions: After nearly 20 years of follow-up among men with localized prostate cancer, surgery was not associated with significantly lower all-cause or prostate-cancer mortality than observation. Surgery was associated with a higher frequency of adverse events than observation but a lower frequency of treatment for disease progression, mostly for asymptomatic, local, or biochemical progression. (Funded by the Department of Veterans Affairs and others; PIVOT ClinicalTrials.gov number, NCT00007644 .).
Comment in
-
Bei high-risk und low-risk scheint Observation auszureichen.Aktuelle Urol. 2017 Sep;48(5):420. doi: 10.1055/s-0043-118398. Epub 2017 Aug 30. Aktuelle Urol. 2017. PMID: 28854473 German. No abstract available.
-
Prostatectomy versus Observation for Early Prostate Cancer.N Engl J Med. 2017 Sep 28;377(13):1302. doi: 10.1056/NEJMc1710384. N Engl J Med. 2017. PMID: 28953432 No abstract available.
-
Prostatectomy versus Observation for Early Prostate Cancer.N Engl J Med. 2017 Sep 28;377(13):1301-2. doi: 10.1056/NEJMc1710384. N Engl J Med. 2017. PMID: 28976174 No abstract available.
-
Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.Eur Urol. 2018 Feb;73(2):303-304. doi: 10.1016/j.eururo.2017.10.008. Epub 2017 Oct 31. Eur Urol. 2018. PMID: 29097095 No abstract available.
-
Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy.Evid Based Med. 2017 Dec;22(6):222. doi: 10.1136/ebmed-2017-110837. Epub 2017 Nov 10. Evid Based Med. 2017. PMID: 29127213 No abstract available.
-
In localized prostate cancer, radical prostatectomy and observation did not differ for mortality at 13 years.Ann Intern Med. 2017 Nov 21;167(10):JC53. doi: 10.7326/ACPJC-2017-167-10-053. Ann Intern Med. 2017. PMID: 29159379 No abstract available.
-
Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.Eur Urol. 2018 Feb;73(2):302-303. doi: 10.1016/j.eururo.2017.11.009. Epub 2017 Nov 23. Eur Urol. 2018. PMID: 29174482 No abstract available.
-
[Which patients with localized prostate cancer benefit from which local procedure and what does "benefit" mean in prostate cancer?].Strahlenther Onkol. 2018 Feb;194(2):174-177. doi: 10.1007/s00066-017-1243-5. Strahlenther Onkol. 2018. PMID: 29264623 German. No abstract available.
-
Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.J Urol. 2018 Feb;199(2):342-343. doi: 10.1016/j.juro.2017.11.033. Epub 2017 Nov 9. J Urol. 2018. PMID: 29357561 No abstract available.
Similar articles
-
Radical prostatectomy versus observation for localized prostate cancer.N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162. N Engl J Med. 2012. PMID: 22808955 Free PMC article. Clinical Trial.
-
Radical prostatectomy versus deferred treatment for localised prostate cancer.Cochrane Database Syst Rev. 2020 Jun 4;6(6):CD006590. doi: 10.1002/14651858.CD006590.pub3. Cochrane Database Syst Rev. 2020. PMID: 32495338 Free PMC article.
-
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.JAMA. 2017 Mar 21;317(11):1126-1140. doi: 10.1001/jama.2017.1704. JAMA. 2017. PMID: 28324093 Free PMC article.
-
Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).Eur Urol. 2020 Jun;77(6):713-724. doi: 10.1016/j.eururo.2020.02.009. Epub 2020 Feb 21. Eur Urol. 2020. PMID: 32089359 Clinical Trial.
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
Cited by
-
Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.J Immunol Res. 2022 Jul 21;2022:4065580. doi: 10.1155/2022/4065580. eCollection 2022. J Immunol Res. 2022. PMID: 35910852 Free PMC article.
-
Active surveillance for intermediate-risk prostate cancer.World J Urol. 2022 Jan;40(1):79-86. doi: 10.1007/s00345-021-03893-1. Epub 2022 Jan 19. World J Urol. 2022. PMID: 35044491 Review.
-
Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?World J Urol. 2018 Aug;36(8):1225-1231. doi: 10.1007/s00345-018-2251-5. Epub 2018 Mar 16. World J Urol. 2018. PMID: 29549484
-
The future of active surveillance.Transl Androl Urol. 2018 Apr;7(2):256-259. doi: 10.21037/tau.2018.01.12. Transl Androl Urol. 2018. PMID: 29732284 Free PMC article. No abstract available.
-
Impact of Robotic Technologies on Prostate Cancer Patients' Choice for Radical Treatment.J Pers Med. 2023 May 5;13(5):794. doi: 10.3390/jpm13050794. J Pers Med. 2023. PMID: 37240964 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical